Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pTVG-HP and Nivolumab in Non-Castrate Recurrent Oligometastatic Prostate Cancer
NCT07090148Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2026
- Primary completion
- Oct 2030
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pTVG-HP plasmid DNA vaccine in prostate cancer (PCa), sponsored by University of Wisconsin–Madison. Primary endpoints: Prostate-Specific Antigen Complete Response Rate at 12 months, Incidence of Adverse Events at 5 years and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
pTVG-HP plasmid DNA vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07090148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090148.